PDF(Pubmed)
Abstract：
UNASSIGNED: Hormone receptor (HR)-low/HER2-negative breast cancers (BCs) are more likely to be basal-like BCs, with similar molecular features and gene expression profiles to HR-negative (estrogen receptor <1% or negative and progesterone receptor <1% or negative) BCs. Recently, with the clinical application of adjuvant intensive therapy for triple-negative breast cancer (TNBC), the prognosis of TNBC patients without pathological complete response (pCR) has significantly improved. Therefore, it is necessary to reanalyse the prognostic characteristics of clinically high-risk HR-low/HER2-negative BC.
UNASSIGNED: According to the inclusion and exclusion standards, 288 patients with HR-low/HER2-negative BC and TNBC who received NAC and were followed up between 2015 and 2022 at three breast centres in Hunan Province, China, were enrolled. Inverse probability of treatment weighting (IPTW) was utilized to mitigate imbalances in baseline characteristics between the HR-low/HER2-negative BC group and TNBC group regarding event-free survival (EFS) and overall survival (OS). The primary clinical endpoints were pCR and EFS, while the secondary endpoints included OS, objective response rate (ORR), and clinical benefit rate (CBR).
UNASSIGNED: The pCR rate (27.1% vs. 28.0%, P = 1.000), ORR rate (76.9% vs. 78.3%, P = 0.827) and CBR rate (89.7% vs. 96.5%, P = 0.113) after NAC were similar between the HR-low/HER2-negative BC and the TNBC group. EFS in patients with non-pCR from the 2 groups was significantly inferior in comparison to patients with pCR (P = 0.001), and the 3-year EFS was 94.74% (95% CI = 85.21% to 100.00%) and 57.39% (95% CI =43.81% to 75.19%) in patients with pCR and non-pCR from the HR-low/HER2-negative BC group, respectively, and 89.70% (95% CI = 82.20% to 97.90%) and 69.73% (95% CI = 62.51% to 77.77%) in the TNBC patients with pCR and non-pCR, respectively.
UNASSIGNED: In the real world, the therapeutic effects of NAC for HR-low/HER2-negative BCs and TNBCs were similar. EFS of patients with non-pCR in the HR-low/HER2-negative BC group was inferior to that of the TNBC group with non-pCR, suggesting that it is necessary to explore new adjuvant intensive therapy strategies for these patients.
UNASSIGNED: According to the inclusion and exclusion standards, 288 patients with HR-low/HER2-negative BC and TNBC who received NAC and were followed up between 2015 and 2022 at three breast centres in Hunan Province, China, were enrolled. Inverse probability of treatment weighting (IPTW) was utilized to mitigate imbalances in baseline characteristics between the HR-low/HER2-negative BC group and TNBC group regarding event-free survival (EFS) and overall survival (OS). The primary clinical endpoints were pCR and EFS, while the secondary endpoints included OS, objective response rate (ORR), and clinical benefit rate (CBR).
UNASSIGNED: The pCR rate (27.1% vs. 28.0%, P = 1.000), ORR rate (76.9% vs. 78.3%, P = 0.827) and CBR rate (89.7% vs. 96.5%, P = 0.113) after NAC were similar between the HR-low/HER2-negative BC and the TNBC group. EFS in patients with non-pCR from the 2 groups was significantly inferior in comparison to patients with pCR (P = 0.001), and the 3-year EFS was 94.74% (95% CI = 85.21% to 100.00%) and 57.39% (95% CI =43.81% to 75.19%) in patients with pCR and non-pCR from the HR-low/HER2-negative BC group, respectively, and 89.70% (95% CI = 82.20% to 97.90%) and 69.73% (95% CI = 62.51% to 77.77%) in the TNBC patients with pCR and non-pCR, respectively.
UNASSIGNED: In the real world, the therapeutic effects of NAC for HR-low/HER2-negative BCs and TNBCs were similar. EFS of patients with non-pCR in the HR-low/HER2-negative BC group was inferior to that of the TNBC group with non-pCR, suggesting that it is necessary to explore new adjuvant intensive therapy strategies for these patients.
摘要：
■激素受体（HR）-低/HER2阴性乳腺癌（BCs）更可能是基底样BCs，与HR阴性（雌激素受体<1％或阴性，孕激素受体<1％或阴性）BCs具有相似的分子特征和基因表达谱。最近,随着三阴性乳腺癌（TNBC）辅助强化治疗的临床应用，无病理完全缓解(pCR)的TNBC患者预后有明显改善。因此,有必要重新分析临床高危HR低/HER2阴性BC的预后特征.
■根据纳入和排除标准，288例HR低/HER2阴性BC和TNBC患者接受NAC治疗，2015年至2022年在湖南省三个乳腺中心进行随访。中国,已注册。利用治疗权重的逆概率(IPTW)来减轻低HR/HER2阴性BC组和TNBC组之间关于无事件生存期(EFS)和总生存期(OS)的基线特征的不平衡。主要临床终点是pCR和EFS，而次要端点包括操作系统，客观反应率（ORR），和临床获益率(CBR)。
■pCR率（27.1%与28.0%,P=1.000),ORR率（76.9%与78.3%,P=0.827）和CBR率（89.7%vs.96.5%,HR低/HER2阴性BC和TNBC组之间的NAC后P=0.113）相似。两组非pCR患者的EFS明显低于pCR患者（P=0.001），HR低/HER2阴性BC组pCR和非pCR患者的3年EFS分别为94.74％（95％CI=85.21％至100.00％）和57.39％（95％CI=43.81％至75.19％），分别,在pCR和非pCR的TNBC患者中，分别为89.70％（95％CI=82.20％至97.90％）和69.73％（95％CI=62.51％至77.77％），分别。
■在现实世界中,NAC对低HR/HER2阴性BC和TNBC的治疗效果相似.HR低/HER2阴性BC组非pCR患者的EFS低于非pCR的TNBC组，提示有必要为这些患者探索新的辅助强化治疗策略。
■根据纳入和排除标准，288例HR低/HER2阴性BC和TNBC患者接受NAC治疗，2015年至2022年在湖南省三个乳腺中心进行随访。中国,已注册。利用治疗权重的逆概率(IPTW)来减轻低HR/HER2阴性BC组和TNBC组之间关于无事件生存期(EFS)和总生存期(OS)的基线特征的不平衡。主要临床终点是pCR和EFS，而次要端点包括操作系统，客观反应率（ORR），和临床获益率(CBR)。
■pCR率（27.1%与28.0%,P=1.000),ORR率（76.9%与78.3%,P=0.827）和CBR率（89.7%vs.96.5%,HR低/HER2阴性BC和TNBC组之间的NAC后P=0.113）相似。两组非pCR患者的EFS明显低于pCR患者（P=0.001），HR低/HER2阴性BC组pCR和非pCR患者的3年EFS分别为94.74％（95％CI=85.21％至100.00％）和57.39％（95％CI=43.81％至75.19％），分别,在pCR和非pCR的TNBC患者中，分别为89.70％（95％CI=82.20％至97.90％）和69.73％（95％CI=62.51％至77.77％），分别。
■在现实世界中,NAC对低HR/HER2阴性BC和TNBC的治疗效果相似.HR低/HER2阴性BC组非pCR患者的EFS低于非pCR的TNBC组，提示有必要为这些患者探索新的辅助强化治疗策略。
